TABLE OF CONTENTS
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW OF GLOBAL PREBIOTICS FOR INFANT FORMULA MARKET 38
1.4 CURRENCY AND PRICING 40
1.5 LIMITATIONS 40
1.6 MARKETS COVERED 40
2 MARKET SEGMENTATION 44
2.1 MARKETS COVERED 44
2.2 GEOGRAPHICAL SCOPE 45
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 DBMR TRIPOD DATA VALIDATION MODEL 47
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.6 DBMR MARKET POSITION GRID 51
2.7 MULTIVARIATE MODELING 53
2.8 PRODUCT TIMELINE CURVE 53
2.9 SECONDARY SOURCES 54
2.10 ASSUMPTIONS 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 57
5 EVOLUTION 58
5.1 EVOLUTION OF INFANT FORMULA 58
5.2 EVOLUTION OF PREBIOTICS FORMULA 59
6 REGULATIONS & QUALITY REQUIREMENTS 60
6.1 REGULATIONS 60
6.1.1 FDA 60
6.1.1.1 GRAS NOTICE NO. GRN 000849 60
6.1.1.2 GRAS NOTICE NO. GRN 00859 60
6.1.1.3 GRAS NOTICE NO. GRN 000797 60
6.1.1.4 GRAS NOTICE NO. GRN 000766 60
6.1.1.5 GRAS Notice No. GRN 000749 60
6.1.1.6 GRAS Notice No. GRN 000735 60
6.1.1.7 GRAS Notice No. GRN 000729 60
6.1.1.8 GRAS Notice No. GRN 000717 60
6.1.1.9 GRAS Notice No. GRN 000721 60
6.1.1.10 GRAS Notice No. GRN 000659 61
6.1.1.11 GRAS Notice No. GRN 000650 61
6.1.1.12 GRAS Notice No. GRN 000623 61
6.1.1.13 GRAS Notice No. GRN 000620 61
6.1.2 EUROPEAN UNION 61
6.1.2.1 COMMISSION DIRECTIVE 2006/141/EC 61
6.1.3 AUSTRALIA NEW ZEALAND FOOD STANDARDS CODE 61
6.1.3.1 STANDARD 2.9.1 61
6.1.3.2 STANDARD 2.9.2 61
6.1.3.3 STANDARD 2.9.3 61
6.2 QUALITY REQUIREMENTS 62
7 CLINICAL TRIALS 63
7.1 NCT03994315 63
7.2 NCT03884309 63
7.3 NCT02594683 63
7.4 NCT03661736 64
7.5 NCT03666572 64
7.6 NCT03866837 64
7.7 NCT03476889 65
8 INFANT FORMULA BRAND ANALYSTS 66
8.1 ABBOTT 66
8.2 MEAD JOHNSON & COMPANY, LLC 66
8.3 DANONE NUTRICIA 67
8.4 NESTLE 67
8.5 PERRIGO NUTRITIONALS 68
8.6 HOCHDORF HOLDING AG 68
9 MARKET OVERVIEW 69
9.1 DRIVERS 71
9.1.1 RISING NUMBER FROM PRETERM/PREMATURE BABIES 71
9.1.2 INCREASED RESEARCH INITIATIVE FOR NEW PRODUCT DEVELOPMENT 71
9.1.3 HEALTH BENEFITS ASSOCIATED WITH PREBIOTICS 72
9.1.4 GROWING CONCERN AND DEMAND FOR THE HEALTHY BABY FOOD 73
9.1.5 RISING POPULATION OF INFANT 73
9.2 RESTRAINTS 74
9.2.1 STRINGENT REGULATION AND APPROVAL CRITERIA SET BY GOVERNMENTS 74
9.2.2 RISING AWARENESS TOWARDS MOTHER FEEDING FOR INFANT 75
9.3 OPPORTUNITIES 75
9.3.1 RAPID DEVELOPMENT IN CHICORY ROOT BASED PREBIOTICS 75
9.3.2 EMERGING DEMAND IN DEVELOPING NATIONS 76
9.3.3 STRENGTHENING TRADE RELATIONSHIP BETWEEN DIFFERENT NATIONS 76
9.4 CHALLENGE 77
9.4.1 RISING NUMBER OF PRODUCT RECALLS FOR INFANT FORMULA DUE TO CONTAMINATION 77
10 GLOBAL PREBIOTICS FOR INFANT FORMULA MARKET, BY TYPE 78
10.1 OVERVIEW 79
10.2 HUMAN MILK OLIGOSACCHARIDES (HMOS) 80
10.2.1 FUCOSYLLACTOSE 82
10.2.1.1 NEUTRAL FUCOSYLATE OLIGOSACCHARIDES 82
10.2.1.2 NON-FUCOSYLATED OLIGOSACCHARIDES 82
10.2.2 LACTO-N- TETRAOSE (LNT) & LACTO-N-NEOTETRAOSE (LNNT) 82
10.2.3 SIALYLLACTOSE 82
10.3 FRUCTOOLIGOSACCHARIDES (FOS) 83
10.3.1 LONG CHAIN FOS (LCFOS) 83
10.3.2 SINGLE CHAIN FOS (SCFOS) 84
10.4 GALACTOOLIGOSACCHARIDES (GOS) 84
10.4.1 LACTOSE DERIVED 84
10.4.2 GALACTOSE DERIVED 85
10.5 INULIN 85
10.6 POLYDEXTROSE (PDX) 85
10.7 MANNAN-OLIGOSACCHARIDES (MOS) 86
10.8 LACTULOSE (LOS) 87
11 GLOBAL PREBIOTICS FOR INFANT FORMULA MARKET, BY SOURCE 88
11.1 OVERVIEW 89
11.2 PLANTS & VEGETABLES 90
11.2.1 WHEAT 91
11.2.2 CHICORY ROOT 91
11.2.3 BANANAS 91
11.2.4 LEEKS 91
11.2.5 TOMATOES 91
11.2.6 OTHERS 91
11.3 BACTERIA 92
11.4 FUNGI 93
11.5 ALGAE 93
11.6 OTHERS 94
12 GLOBAL PREBIOTICS FOR INFANT FORMULA MARKET, BY GRADE 95
12.1 OVERVIEW 96
12.2 INORGANIC 97
12.3 ORGANIC 97
13 GLOBAL PREBIOTICS FOR INFANT FORMULA MARKET, BY FORM 99
13.1 OVERVIEW 100
13.2 POWDER 101
13.3 LIQUID 102
14 GLOBAL PREBIOTICS FOR INFANT FORMULA MARKET, BY PRODUCT TYPE 103
14.1 OVERVIEW 104
14.2 STANDARD FORMULA 105
14.3 SPECIAL FORMULA 105
14.4 FOLLOW UP FORMULA 106
14.5 TODDLER FORMULA 107
15 GLOBAL PREBIOTICS FOR INFANT FORMULA MARKET, BY INFANT AGE 108
15.1 OVERVIEW 109
15.2 6-12 MONTHS 110
15.3 0-6 MONTHS 110
15.4 1-3 YEARS 111
16 GLOBAL PREBIOTICS FOR INFANT FORMULA MARKET, BY GEOGRAPHY 112
16.1 OVERVIEW 113
16.2 NORTH AMERICA 118
16.2.1 U.S. 125
16.2.2 CANADA 128
16.2.3 MEXICO 131
16.3 ASIA-PACIFIC 134
16.3.1 JAPAN 141
16.3.2 CHINA 144
16.3.3 SOUTH KOREA 147
16.3.4 INDIA 150
16.3.5 AUSTRALIA 153
16.3.6 SINGAPORE 157
16.3.7 MALAYSIA 160
16.3.8 THAILAND 163
16.3.9 INDONESIA 166
16.3.10 PHILIPPINES 169
16.3.11 NEW ZEALAND 172
16.3.12 VIETNAM 175
16.3.13 REST OF ASIA-PACIFIC 178
16.4 EUROPE 179
16.4.1 GERMANY 186
16.4.2 U.K. 190
16.4.3 FRANCE 193
16.4.4 ITALY 196
16.4.5 SPAIN 199
16.4.6 DENMARK 202
16.4.7 NETHERLANDS 205
16.4.8 SWITZERLAND 208
16.4.9 POLAND 211
16.4.10 RUSSIA 214
16.4.11 SWEDEN 217
16.4.12 BELGIUM 220
16.4.13 TURKEY 223
16.4.14 REST OF EUROPE 226
16.5 SOUTH AMERICA 227
16.5.1 BRAZIL 233
16.5.2 ARGENTINA 236
16.5.3 REST OF SOUTH AMERICA 239
16.6 MIDDLE EAST & AFRICA 240
16.6.1 SOUTH AFRICA 247
16.6.2 U.A.E. 250
16.6.3 SAUDI ARABIA 253
16.6.4 OMAN 256
16.6.5 KUWAIT 259
16.6.6 REST OF MIDDLE EAST & AFRICA 262
17 GLOBAL PREBIOTICS FOR INFANT FORMULA MARKET, COMPANY LANDSCAPE 263
17.1 COMPANY SHARE ANALYSIS: GLOBAL 263
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 264
17.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 265
17.4 COMPANY SHARE ANALYSIS: EUROPE 266
17.5 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 267
?
18 COMPANY PROFILE 268
18.1 ROYAL FRIESLANDCAMPINA N.V. 268
18.1.1 COMPANY SNAPSHOT 268
18.1.2 REVENUE ANALYSIS 268
18.1.3 COMPANY SHARE ANALYSIS 269
18.1.4 PRODUCT PORTFOLIO 269
18.1.5 RECENT DEVELOPMENTS 270
18.2 CARGILL, INCORPORATED. 271
18.2.1 COMPANY SNAPSHOT 271
18.2.2 REVENUE ANALYSIS 271
18.2.3 COMPANY SHARE ANALYSIS 272
18.2.4 PRODUCT PORTFOLIO 272
18.2.5 RECENT DEVELOPMENT 272
18.3 INGREDION INCORPORATED 273
18.3.1 COMPANY SNAPSHOT 273
18.3.2 REVENUE ANALYSIS 273
18.3.3 COMPANY SHARE ANALYSIS 274
18.3.4 PRODUCT PORTFOLIO 274
18.3.5 RECENT DEVELOPMENT 274
18.4 BENEO (A SUBSIDIARY OF SuDZUCKER) 275
18.4.1 COMPANY SNAPSHOT 275
18.4.2 REVENUE ANALYSIS 275
18.4.3 COMPANY SHARE ANALYSIS 276
18.4.4 PRODUCT PORTFOLIO 276
18.4.5 RECENT DEVELOPMENTS 276
18.5 FONTERRA CO-OPERATIVE GROUP 277
18.5.1 COMPANY SNAPSHOT 277
18.5.2 REVENUE ANALYSIS 278
18.5.3 COMPANY SHARE ANALYSIS 278
18.5.4 PRODUCT PORTFOLIO 279
18.5.5 RECENT DEVELOPMENTS 279
18.6 BIOSYNTH CARBOSYNTH 280
18.6.1 COMPANY SNAPSHOT 280
18.6.2 PRODUCT PORTFOLIO 280
18.6.3 RECENT DEVELOPMENTS 281
18.7 COSUCRA 282
18.7.1 COMPANY SNAPSHOT 282
18.7.2 PRODUCT PORTFOLIO 282
18.7.3 RECENT DEVELOPMENTS 282
?
18.8 DANA DAIRY GROUP 283
18.8.1 COMPANY SNAPSHOT 283
18.8.2 PRODUCT PORTFOLIO 283
18.8.3 RECENT DEVELOPMENTS 283
18.9 DEXTRA LABORATORIES LIMITED 284
18.9.1 COMPANY SNAPSHOT 284
18.9.2 PRODUCT PORTFOLIO 284
18.9.3 RECENT DEVELOPMENT 284
18.10 DUPONT. 285
18.10.1 COMPANY SNAPSHOT 285
18.10.2 REVENUE ANALYSIS 286
18.10.3 PRODUCT PORTFOLIO 286
18.10.4 RECENT DEVELOPMENTS 286
18.11 ELICITYL SA 287
18.11.1 COMPANY SNAPSHOT 287
18.11.2 PRODUCT PORTFOLIO 287
18.11.3 RECENT DEVELOPMENT 287
18.12 GLYCOM A/S 288
18.12.1 COMPANY SNAPSHOT 288
18.12.2 PRODUCT PORTFOLIO 288
18.12.3 RECENT DEVELOPMENT 288
18.13 GLYCOSYN LLC. 289
18.13.1 COMPANY SNAPSHOT 289
18.13.2 PRODUCT PORTFOLIO 289
18.13.3 RECENT DEVELOPMENTS 289
18.14 JENNEWEIN BIOTECHNOLOGIE GMBH 290
18.14.1 COMPANY SNAPSHOT 290
18.14.2 PRODUCT PORTFOLIO 290
18.14.3 RECENT DEVELOPMENTS 291
18.15 NEW FRANCISCO (YUNFU CITY) BIOTECHNOLOGY CORPORATION LIMITED 292
18.15.1 COMPANY SNAPSHOT 292
18.15.2 PRODUCT PORTFOLIO 292
18.15.3 RECENT DEVELOPMENTS 292
18.16 ROYAL COSUN 293
18.16.1 COMPANY SNAPSHOT 293
18.16.2 REVENUE ANALYSIS 293
18.16.3 APPLICATION PORTFOLIO 294
18.16.4 RECENT DEVELOPMENT 294
?
18.17 TEREOS 295
18.17.1 COMPANY SNAPSHOT 295
18.17.2 REVENUE ANALYSIS 295
18.17.3 PRODUCT PORTFOLIO 296
18.17.4 RECENT DEVELOPMENT 296
18.18 ZUCHEM INC. 297
18.18.1 COMPANY SNAPSHOT 297
18.18.2 PRODUCT PORTFOLIO 297
18.18.3 RECENT DEVELOPMENT 297
19 QUESTIONNAIRE 298
20 RELATED REPORTS 301